IDIX (MM)

Today, www.EquityMarketsInc.com announced its research report highlighting Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Full content and research is available at www.EquityMarketsInc.com/research.php?id=IDIX+BCRX.

Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments" weary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.

As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.

Equity Markets has reviewed Idenix Pharmaceuticals, Inc. for its current position within the healthcare industry. Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's research and development focus is on the treatment of hepatitis C virus (HCV). The full research report on Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) is available here: www.EquityMarketsInc.com/research.php?id=IDIX.

Equity Markets has reviewed BioCryst Pharmaceuticals, Inc. for its development within the healthcare industry. BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company that designs, optimizes and develops novel drugs that block enzymes involved in cancer, viral infections and autoimmune diseases. The full research report on BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is available here: www.EquityMarketsInc.com/research.php?id=BCRX.

About Equity Markets Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact: Samuel Littman Email Contact www.EquityMarketsInc.com